Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C by Angela Costantino et al.
SHORT REPORT Open Access
Naturally occurring mutations associated
with resistance to HCV NS5B polymerase
and NS3 protease inhibitors in treatment-
naïve patients with chronic hepatitis C
Angela Costantino1* , Enea Spada1, Michele Equestre2, Roberto Bruni1, Elena Tritarelli1, Nicola Coppola3,
Caterina Sagnelli4, Evangelista Sagnelli3 and Anna Rita Ciccaglione1
Abstract
Background: The detection of baseline resistance mutations to new direct-acting antivirals (DAAs) in HCV
chronically infected treatment-naïve patients could be important for their management and outcome prevision. In
this study, we investigated the presence of mutations, which have been previously reported to be associated with
resistance to DAAs in HCV polymerase (NS5B) and HCV protease (NS3) regions, in sera of treatment-naïve patients.
Findings: HCV RNA from 152 naïve patients (84 % Italian and 16 % immigrants from various countries) infected
with different HCV genotypes (21,1a; 21, 1b; 2, 2a; 60, 2c; 22, 3a; 25, 4d and 1, 4k) was evaluated for sequence
analysis. Amplification and sequencing of fragments in the NS5B (nt 8256–8640) and NS3 (nt 3420–3960) regions of
HCV genome were carried out for 152 and 28 patients, respectively. The polymorphism C316N/H in NS5B region,
associated with resistance to sofosbuvir, was detected in 9 of the 21 (43 %) analysed sequences from genotype
1b-infected patients. Naturally occurring mutations V36L, and M175L in the NS3 protease region were observed in
100 % of patients infected with subtype 2c and 4.
Conclusion: A relevant proportion of treatment naïve genotype 1b infected patients evaluated in this study
harboured N316 polymorphism and might poorly respond to sofosbuvir treatment. As sofosbuvir has been
approved for treatment of HCV chronic infection in USA and Europe including Italy, pre-treatment testing for N316
polymorphism on genotype 1b naïve patients should be considered for this drug.
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Background
Hepatitis C virus (HCV) is a global health problem. Ap-
proximately 3 % of the world population is infected with
HCV, the leading cause of liver cirrhosis, hepatic decom-
pensation, development of hepatocellular carcinoma
(HCC) and liver transplantations worldwide [1]. HCV is
characterized by a high genetic heterogeneity and is clas-
sified in 7 genotypes and numerous subtypes [2]. Some
subtypes are ubiquitous while others circulate in particu-
lar regions [3]. In Italy, the prevalence of HCV is
declining. Recent studies carried out among general
population in both northern and southern Italy have re-
ported an anti-HCV prevalence ranging from 2.6 to 5.7
[4–6]. However it is a common opinion among re-
searchers that at present in Italy the prevalence of HCV
chronic carriers is about 1–1.5 %. The most frequent ge-
notypes circulating in general population are 1b, 2c and,
to a less extent, 3a, while the prevalence of genotype 4
has increased in recent years, in southern regions [6–8].
Pegylated-Interferon plus ribavirin (peg-IFN-RBV) has
been the standard-of-care treatment for chronic hepatitis
C for many years, although it had some disadvantages,
such as a suboptimal therapy response rate in some pa-
tients’ subsets (genotype 1 and 4 infections, advanced
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liver fibrosis) and side effects often resulting in poor tol-
erability and treatment contraindication [9]. Recently,
new anti-HCV drugs, termed direct-acting antiviral
agents (DAAs) have been developed. DAAs target differ-
ent regions of HCV genome and can be distinguished in
NS3/4A protease inhibitors (PIs), NS5A inhibitors,
NS5B nucleoside (NPIs) and non-nucleoside polymerase
inhibitors (NNPIs). Boceprevir and Telaprevir, first gen-
eration NS3 PIs, were approved in the 2011 in United
States by Food and Drug Administration and Europe
(FDA) by European Medicines Agency (EMA) for ther-
apy of chronic hepatitis C. These drugs, however, admin-
istered in combination with peg-IFN and ribavirin were
hampered by a low efficacy against non-1 genotypes, ser-
ious adverse reactions and low genetic barrier to resist-
ance. In addition to the first generation PIs, two new
NS3 PIs (Simeprevir and Faldaprevir) one NS5A inhibi-
tor (Dataclasvir) and one NS5B NPI (Sofosbuvir) have
been recently (FDA, EMA, 2014) approved for treatment
of chronic hepatitis C [10]. The most recent DAAs in-
crease response rates, allow shortened and simplified
regimens and have a higher genetic barrier to resistance
[11]. However, the effectiveness of new DAAs may be af-
fected by the development of drug-resistance mutations.
Due to the high sequence diversity, high replication rate
and low fidelity of HCV RNA-polymerase, numerous
variants, defined as quasispecies, exist in vivo in a HCV
infected patient [12]. Some of these variants can carry
amino-acid substitutions which determine conformation
changes of a drug binding site, thus causing resistance
during therapy [13, 14]. These drug resistance substitu-
tions, which usually emerge after a few days of DAAs
treatment and are responsible for treatment failure (par-
ticularly with first generation drugs) [15, 16] or hypore-
sponsiveness to treatment, can also be found in HCV
infected treatment-naïve patients [17–23]. These natur-
ally resistant variants have been reported to occur at
variable frequencies and are genotype/subtype
dependent. In fact, the frequency of natural resistance
mutations to first generation NS3 PIs is lower in geno-
type 1b compared to genotype 1a patients [19]. Resist-
ance mutations to NS3 PIs in treatment-naïve patients
infected with non-1 genotypes have been investigated in
several studies, but only one of them detected two prin-
cipal mutations (V158M for genotype 2c and D168E for
genotype 4) in a significant number of patients infected
with genotypes 2c and 4 [23]. On the contrary, many
substitutions associated with resistance to NS3 PIs have
been reported for genotype 1 [24]. The S282T mutation
in NS5B polymerase region, identified in vitro [25] and
in vivo in a 2b infected patient who failed therapy during
a clinical trial [26, 27], is the only mutation so far surely
associated with resistance to sofosbuvir. Indeed, several
other NS5B substitutions have also been suggested as re-
sponsible for sofosbuvir treatment failure [28]. In par-
ticular, a baseline NS5B polymorphism at position 316
has been potentially associated with reduced response
rates to sofosbuvir in genotype 1b patients [29]. The aim
of this study was to investigate the presence of variants
resistant to DAAs in the NS5B polymerase and NS3
serine protease regions by analysing patients with
chronic hepatitis C who had not been treated with any
DAAs.
Materials and methods
This study included 152 DAA-naïve patients chronically
infected with HCV genotype 1a (n = 21), 1b (n = 21), 2a
(n = 2), 2c (n = 60), 3a (n = 22), 4d (n = 25) and 4 k (n =
1) [6–8], and analysed for NS5B region (nt 8256–8640)
using primers and amplification conditions reported
elsewhere [4, 6–8]. For 28 (11, 1b; 11, 2c and 6, 4d) of
these 152 patients, HCV-NS3 region (3420–3960) was
also amplified by nested PCR using in the first round
primers and amplification conditions previously reported
[30]. In the second round, new designed primers and a
different thermal cycle program were used, while all
other amplification conditions (buffer, primers’ concen-
tration, etc.) were the same as those used in the first
Table 1 Primers used for HCV NS3 protease gene amplification
HCV
genotype
I-PCR primers II-PCR primers 5’-3’ sequenceb H77 location
1b MarsF2aMarsR1a NS31b FbMarsR2a 5'- TRCCHGTCTCCGCCCGVAG-3'c 3291-33104215–42373340–33584035-4054
2c MarsF1aMarsR1a NS3 2c FbNS3 2c Rb 5'- TGGGCCCTGCTGATGGATAC-3'd5'-
GTAGGTCTGGGGCACAGCTG-3'
3291-33104215–42373376–33954010-3991
4d G4F1aG4R1a NS3 4d FbNS3 4d Rb 5’-ATGCGCACRCYAYGAAGGG-3’e5’-
GGCACGGCAGGAGGAGTGGA-3’
3369-33883997–40183388–34074000-3981
a Previously published primers (Vallet S [30])
b Primers selected by alignment of sequences from Los Alamos databank
c Amplification conditions in the second PCR for genotype 1b, were: 2’ at 94 °C, and then 30 cycles at 94 °C for 30”, 60 °C for 30” and 72 °C for 45”, plus extension
at 72 °C for 7’
d Amplification conditions in the second PCR for genotype 2c, were: 2’at 94 °C, and then 30 cycles at 94 °C for 30”, 62 °C for 30” and 72 °C for 45”, plus extension
at 72 °C for 7’
e Amplification conditions in the second PCR for genotype 4, were: 2’at 94 °C, and then 30 cycles at 94 °C for 30”, 60 °C for 40” and 72 °C for 45”, plus extension at
72 °C for 7’
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PCR round (Table 1). An automated DNA sequencer
(Beckman Coulter, Inc., Fullerton, CA) was used for se-
quencing. Nucleotide sequences were assembled using
Chromas software, and aligned using ClustalW package.
Results
A total of 152 patients (81 males and 55 females; me-
dian age 47, range 20–90 years) were analysed. About
84 % (127/152) of these patients were of Italian ori-
gin, while the remaining 25 patients were immigrants
from various countries. From sera of these patients
were obtained 152 NS5B and 28 NS3 sequences. All
aminoacid substitutions in NS5B polymerase and NS3
protease regions potentially associated with resistance
to DAAs in HCV- infected treatment-naive patients
in this study, are shown in Tables 2 and 3, respect-
ively. The NS5B polymerase fragment of all analysed
genotypes showed no mutation known to induce high
level of resistance to sofosbuvir in vitro (S282T), as
well as other mutations recently regarded as respon-
sible for sofosbuvir treatment failure in clinical trials
(V321I/A, L320F/C) [22]. Whereas, the polymorphism
C316N/H, potentially associated with reduced re-
sponse rates to sofosbuvir in genotype 1b HCV
chronically infected patients [23], was found in 9 of
21 (43 %) analysed 1b sequences (C316N and C316H
polymorphisms were detected in 8 and in 1 patients,
respectively). No substitutions conferring resistance to
both first generation and new NS3 PIs (Simeprevir
and Faldaprevir), were observed in the NS3 region of
genotype 1b sequences. Instead, the V36L and M175L
substitutions, know to induce decreased susceptibility
exclusively to first generation PIs in genotype 1 infec-
tions, were naturally present in NS3 region of geno-
type 2c and 4d sequences.
Finally, several polymorphisms not associated with re-
sistance to DAAs and already reported by others [18]
were observed in NS3 region of our analysed-genotypes
(Tables 4, 5 and 6).
Discussion
This study reports the results of the HCV sequencing
from 152 treatment-naïve patients chronically infected
with different HCV genotypes. In these patients, we eval-
uated the presence of known drug resistance mutations
focusing on NS5B polymerase and NS3 protease regions.
Aminoacid substitutions, such as V36L and M175L, as-
sociated with HCV-genotype 1 PIs resistance in vivo and
in vitro, were naturally observed in 100 % of our patients
Table 3 Aminoacid substitutions in HCV NS3 protease region associated with resistance to DAAsa in treatment-naïve patients
Rb Pc Dd Me Drug G 1b (n = 11) G 2c (n = 11) G 4d (n = 6)
NS3 16 C S ACH806 *C/R(9) *A(100) *T(100)
NS3 36 V A,M,G,L Telaprevir, Boceprevir *V(100) L(100)f L(100)f
NS3 54 T A,S Telaprevir, Boceprevir • • •
NS3 155 R K,T,I,MG,L,S,Q Telaprevir, Boceprevir • • •
NS3 156 A S,T,V,I Telaprevir, Boceprevir • • •
NS3 168 D Q,A,V,E,T TMC435,R7227,MK7009, BI201335, BILN2061 • • •
NS3 175 M L Telaprevir *M(100) L(100)f L(100)f
a direct acting antiviral agents
Rb, Region; Pc,Position aa; Dd,Dominant aa; Me, Mutant aa; (Lopez-Labrador, 2008; Lentz, 2010; Kieffer [15], Halfon [13], Kuntzen [19])
*Percentage of sequences with substitutions
•The dominant residue is found in 100 % of analyzed sequences for each genotype
f Substitution found is associated with resistance in genotype 1b
Table 2 Aminoacid substitutions in HCV NS5B polymerase region associated with resistance to DAAsa in treatment-naïve patients
Rb Pc Dd Me Drug G 1a (n = 21) G 1b (n = 21) G 2a (n = 2) G 2c (n = 60) G 3a (n = 20) G 4d (n = 25) G 4 k (n = 1)
NS5B 316 C N,Y,H Sofosbuvir,
Mericitabine
• *C(57)/N(38),H(5) • • • • •
NS5B 282 S T Sofosbuvir,
Mericitabine
• • • • • • •
NS5B 320 I Sofosbuvir,
Mericitabine
• • • • • • •
NS5B 321 V Sofosbuvir,
Mericitabine
• • • • • • •
a direct acting antiviral agents
Rb, Region; Pc, Position aa; Dd, Dominant aa; Me, Mutant aa; (Donaldson, [29]; Lam, [25]; Tong, [28])
*Percentage of sequences with substitutions
•The dominant residue is found in 100 % of analyzed sequences for each genotype
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infected with genotype 2c and 4d. The impact of this lat-
ter finding on therapy is unclear. Indeed, boceprevir and
telaprevir showed less efficacy against genotype 2, and
almost no efficacy against other non-1 genotypes, in-
cluding genotype 4. We cannot exclude that the re-
ported low efficacy of boceprevir and telaprevir against
genotype 2 and 4 is influenced by the presence of these
natural polymorphisms detected by us and others [23].
The mutations in the NS3 region are rare to detect in
naïve patients. Unfortunately, for tecnical reason the se-
quence analysis of the NS3 region in this study was lim-
ited to 28 serum samples only. However, these
descriptive frequency data could be useful for further
studies that analyse this HCV RNA region in the predic-
tion of HCV antiviral therapy outcome. With regard to
the presence of pre-treatment sofosbuvir resistance mu-
tations, the S282T variant was not found in any of our
patients, regardless of genotype. This is in agreement
with literature data reporting that S282T variants are
mainly found in vitro [25]. It is likely that our negative
result, regarding the detection of this mutation, may be
also due to the limits of the sequencing method used in
this study. Indeed, the Sanger method can potentially mis-
represent the totality of viral quasispecies harboured by an
HCV infected patient [27]. In fact, in a recent study the
S282T variant has been detected by deep sequencing at
0.05 % of viral sequences at baseline in a genotype 2b in-
fected subject who relapsed following 12 weeks of SOF
monotherapy [27]. Besides, other S282 variants (S282R/G/C)
have been identified in naïve subjects [31].
Recently, novel (treatment-emergent) NS5B mutations
(L159F, L320F and V321A) were detected in HCV in-
fected patients who failed sofosbuvir treatment [29]. Im-
portantly, a baseline polymorphism at position 316 has
been associated with sofosbuvir treatment failure in
genotype 1b infected patients [29]. It has been reported
that C316 mutation is positioned closed to the catalytic
triad of the NS5B polymerase and changes at this pos-
ition can prevent binding of sofosbuvir [29]. We have
found substitution 316 N/H in 43 % of genotype 1b se-
quences. The same position, as well as positions 320 and
321, was highly conserved (100 %) in the other analysed
genotypes. The identification of baseline resistance mu-
tations to DAAs could be important for patients’ man-
agement and outcome prevision. In this regard, the
detection of 316 N/H polymorphism in 43 % of our 1b
naive infected patients represents the most relevant find-
ing of this study since these patients might poorly re-
spond to sofosbuvir therapy. Indeed, a recent study
reported that baseline polymorphisms at position 316
were potentially associated with reduced response rates
in HCV genotype 1b subjects [29]. In conclusion, pre-
treatment testing for C316N polymorphism on HCV
genotype 1b seems to be indicated for naïve patients
considered for treatments including sofosbuvir.
Table 6 Polymorphic sites in the HCV-4 NS3 protease not
resistance-associated found in this study
aPositions bSubtype 4 aPositions bSubtype 4
12 G12/R (1) 98 T98/A (1)
13 L13/M (8) 102 A102/S (8)
14 F14/L (8) 105 Y105/F (7)
15 S15/G (7) 114 I114/V (8)
18 V18/I (8) 122 T122/N (1)
24 R24/K (1) 127 L127/I (5)
33 V33/I (4) 133 S133/A (1)
47 A47/S (3) 134 I134/T (8)
48 V48/I (7) 147 M147/L (8)
61 A61/S (8) 150 R150/A (8)
92 R92/K (8) 172 V172/I (1)
95 A95/T (1) 179 M179/A (1)
a The residues are reported as in the wild-type HCV-1a sequence
b The number of patients with mutant HCV strains is indicated in brackets
Table 5 Polymorphic sites not associated with resistance to
DAAs in the HCV 2c NS3 protease







aThe residues are reported as in the wild-type HCV-1a sequence
bThe number of patients with mutant HCV strains is indicated in brackets
Table 4 Polymorphic sites in the HCV 1b NS3 protease region
found in this study
aPosition bSubtype 1b aPosition bSubtype 1b
7 S7/A (6) 114 V114/I (11)
14 L14/V (1) 122 S122/T (1)
30 D30/E (10) 128 S128/Y (1)
48 V48/I (6) 131 P131/T (1)
51 V51/A (1) 132 I132/V/L (5)
56 Y56/F (4) 142 P142/L (1)
61 S61/P/T (5) 150 V150/A (9)
83 V83 /I (1) 170 I170/V (5)




aThe residues are reported as in the wild-type HCV-1a sequence
bThe number of patients with mutant HCV strains is indicated in brackets
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